Dezhan Healthcare Co., Ltd. (SHE: 000813) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for WYY026B Injection, a Category 1 chemical innovative drug developed by its wholly‑owned subsidiary Beijing Honghui Meditech Co., Ltd. (“Honghui Meditech”), for the treatment of acute ischemic stroke (AIS) – a time‑critical neurological emergency with limited therapeutic options and significant unmet need.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Application Type | Investigational New Drug (IND) – approved |
| Product | WYY026B Injection (Category 1 chemical drug) |
| Indication | Acute ischemic stroke (AIS) |
| Sponsor | Beijing Honghui Meditech Co., Ltd. (wholly‑owned subsidiary of Dezhan Healthcare) |
| Approval Date | 9 Oct 2026 |
| Intellectual Property | Independent IP rights held by Honghui Meditech |
| Next Steps | Initiation of Phase I clinical trials in the United States |
Drug Profile & Mechanism of Action
- Molecule: WYY026B – a Category 1 chemical innovative drug (novel molecular entity) with independent intellectual property rights owned by Honghui Meditech
- Mechanism (Multimodal): WYY026B operates through a triple‑action neuroprotective mechanism:
- Cerebral Oxygen Utilization Enhancement: Improves oxygen utilization in brain tissue, directly addressing cerebral hypoxia – the core pathophysiological driver of neuronal death in ischemic stroke
- Antioxidant Activity: Neutralizes reactive oxygen species (ROS) generated during ischemia‑reperfusion injury, reducing oxidative stress‑mediated neuronal damage
- Anti‑Inflammatory Properties: Suppresses neuroinflammatory cascades triggered by acute ischemia, limiting secondary brain injury in the hours and days following stroke onset
- Therapeutic Class: Neuroprotective agent for acute ischemic stroke – a drug class with a long history of clinical trial failures, making any agent with robust preclinical evidence particularly noteworthy
- Development Stage: IND‑approved; preclinical pharmacodynamic studies complete; Phase I clinical trials anticipated
Clinical Context – Preclinical Evidence
| Endpoint | Preclinical Result |
|---|---|
| Neurological Function Scores | Significant improvement vs. control |
| Cerebral Infarction Area | Significant reduction vs. control |
| Cerebral Oxygen Utilization | Enhanced oxygen utilization in brain tissue |
| Oxidative Stress Markers | Reduced (antioxidant effect demonstrated) |
| Neuroinflammation Markers | Reduced (anti‑inflammatory effect demonstrated) |
| Specific Numeric Data | Not disclosed in press release |
Preclinical pharmacodynamic studies demonstrated that WYY026B delivered meaningful improvements across multiple validated stroke outcome measures, including neurological function scores and cerebral infarction volume – two widely accepted translational endpoints in stroke drug development. The multimodal mechanism (oxygen utilization + antioxidant + anti‑inflammatory) is designed to address the complex, multi‑pathway nature of ischemic brain injury, which has been a key reason for failure of single‑mechanism neuroprotective agents in prior clinical trials.
Market Impact & Outlook
- Acute Ischemic Stroke Landscape: AIS accounts for approximately 85 % of all strokes, affecting over 12 million people globally each year. The only FDA‑approved pharmacotherapy for AIS remains intravenous tissue plasminogen activator (tPA / alteplase), which must be administered within a narrow 4.5‑hour therapeutic window and is contraindicated in many patients – leaving the vast majority of stroke patients without acute pharmacological treatment.
- Neuroprotective Drug Gap: Despite decades of research, no neuroprotective agent has achieved FDA approval for acute ischemic stroke, making this one of the most notorious “graveyards” in pharmaceutical development. WYY026B’s multimodal mechanism and robust preclinical profile position it as a candidate that may overcome the limitations of prior single‑target agents.
- U.S. IND Significance: FDA IND clearance enables clinical development in the United States – the world’s largest pharmaceutical market and the regulatory gold standard. A U.S. clinical program significantly elevates the global development and commercial value of the asset.
- Dezhan Healthcare Strategy: This IND approval represents a strategic milestone for Dezhan Healthcare’s innovation pipeline, executed through its subsidiary Honghui Meditech. Successful U.S. clinical development could transform the company’s international profile and create substantial partnership or licensing opportunities.
- Competitive Differentiation: WYY026B’s triple‑action mechanism (oxygen utilization + antioxidant + anti‑inflammatory) differentiates it from most neuroprotective candidates in development, which typically target a single pathway. This multimodal approach aligns with the emerging scientific consensus that effective stroke neuroprotection requires addressing multiple injury cascades simultaneously.
- Next Steps: Phase I clinical trial design, enrollment timelines, and potential partnership discussions Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory trajectory, and commercial potential of WYY026B Injection in acute ischemic stroke. FDA IND approval authorizes clinical trial initiation but does not indicate efficacy or predict regulatory outcomes. Actual results may differ due to risks including clinical trial performance, safety findings, regulatory decisions, and the inherent challenges of neuroprotective drug development.-Fineline Info & Tech
